

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation of the mixture ARRANON INJECTION

Registration number -

Synonyms ARRANON INJECTION 5 MG/ML * ATRIANCE INFUSION * 506u78 INJECTION * GI262250X INJECTION * NDC 0007-4401-01 * NDC 0007-4401-06 * NELARABINE, FORMULATED PRODUCT

Issue date 20-November-2014

Version number 06

Revision date 20-November-2014

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product.

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information (normal business hours): +44-20-8047-5000
Email Address: msds@gsk.com
Website: www.gsk.com

1.4. Emergency telephone number

TRANSPORT EMERGENCIES::
UK In-country toll call: +(44)-870-8200418
International toll call: +1 703 527 3887
available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.3. Other hazards Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
---------------	---	------------------	------------------------	-----------	-------

506U78	0.5	121032-29-9	-	-	
Classification:	DSD:	Carc. Cat. 3;R40, Muta. Cat. 3;R68, Repr. Cat. 3;R62-63, R53			
	CLP:	Muta. 2;H341, Carc. 2;H351, Repr. 2;H361, STOT RE 1;H372, Aquatic Chronic 4;H413			

Other components below reportable levels 99.5

List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

4.1. Description of first aid measures

Inhalation	Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if symptoms develop or persist. Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin contact	Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Get medical attention if symptoms occur.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
Ingestion	If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control centre immediately. Do not induce vomiting without advice from poison control center.

4.2. Most important symptoms and effects, both acute and delayed None known.
The following adverse effects have been noted with therapeutic use of this material: temporary decrease in white blood cell counts; abnormal nervous system sensations; gastrointestinal distress . Prolonged exposure may cause chronic effects.

4.3. Indication of any immediate medical attention and special treatment needed No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

SECTION 5: Firefighting measures

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing media Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing media None known.

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting procedures Move containers from fire area if you can do so without risk.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Keep unnecessary personnel away. For personal protection, see section 8.

For emergency responders Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

6.2. Environmental precautions	Avoid discharge into drains, water courses or onto the ground.
6.3. Methods and material for containment and cleaning up	Large Spills: Stop the flow of material, if this is without risk. Dike the spilled material, where this is possible. Cover with plastic sheet to prevent spreading. Absorb in vermiculite, dry sand or earth and place into containers. Following product recovery, flush area with water. Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination. Never return spills to original containers for re-use.
6.4. Reference to other sections	For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

SECTION 7: Handling and storage

7.1. Precautions for safe handling	Avoid prolonged exposure. Observe good industrial hygiene practices.
7.2. Conditions for safe storage, including any incompatibilities	Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).
7.3. Specific end use(s)	Medicinal Product.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK Components	Type	Value	Note
NELARABINE (CAS 121032-29-9)	8 HR TWA	10 mcg/m ³	
	OHC	4	REPRODUCTIVE HAZARD, CARCINOGEN

Biological limit values No biological exposure limits noted for the ingredient(s).

Recommended monitoring procedures Follow standard monitoring procedures.

Derived no-effect level (DNEL) Not available.

Predicted no effect concentrations (PNECs) Not available.

Exposure guidelines

8.2. Exposure controls

Appropriate engineering controls General ventilation normally adequate.

Individual protection measures, such as personal protective equipment

General information	Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.
Eye/face protection	Not normally needed. If contact is likely, safety glasses with side shields are recommended. (e.g. EN 166).
Skin protection	
- Hand protection	Not normally needed. For prolonged or repeated skin contact use suitable protective gloves. Select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time).
- Other	Not normally needed. Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for splashes, EN ISO 13982 for dust).
Respiratory protection	No personal respiratory protective equipment normally required. When workers are facing concentrations above the exposure limit they must use appropriate certified respirators. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic, inorganic, acid inorganic, alkaline compounds and toxic particles (eg. EN 14387).
Thermal hazards	Wear appropriate thermal protective clothing, when necessary.

Hygiene measures	Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. New or expectant mothers might be at greater risk from overexposure. Risk assessments must take this into consideration. Female employees anticipating pregnancy or with a confirmed pregnancy must be encouraged to notify an occupational health professional or their line manager. This will act as the trigger for individual re-assessment of the employee's work practices.
Environmental exposure controls	
Hazard guidance and control recommendations	Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state	Liquid.
Form	Vial.
Colour	Not available.
Odour	Not available.
Odour threshold	Not available.
pH	Not available.
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Not available.
Solubility (other)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Explosive properties	Not available.
Oxidizing properties	Not available.

9.2. Other information

Percent volatile	99 % estimated
-------------------------	----------------

SECTION 10: Stability and reactivity

10.1. Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
10.2. Chemical stability	Material is stable under normal conditions.
10.3. Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
10.4. Conditions to avoid	Contact with incompatible materials.
10.5. Incompatible materials	Strong oxidising agents.
10.6. Hazardous decomposition products	Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

SECTION 11: Toxicological information

General information Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Inhalation	Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin contact	Health injuries are not known or expected under normal use.
Eye contact	Health injuries are not known or expected under normal use. Direct contact with eyes may cause temporary irritation.
Ingestion	Health injuries are not known or expected under normal use. May be harmful if swallowed. However, ingestion is not likely to be a primary route of occupational exposure.

Symptoms None known.
The following adverse effects have been noted with therapeutic use of this material: temporary decrease in white blood cell counts; abnormal nervous system sensations; gastrointestinal distress.
Prolonged exposure may cause chronic effects.

11.1. Information on toxicological effects

Acute toxicity Health injuries are not known or expected under normal use. May be harmful if swallowed.

Components	Species	Test results
506U78 (CAS 121032-29-9)		
Chronic		
Oral		
LOEL	Monkey	10 mg/kg/day Intravenous route
* Estimates for product may be based on additional component data not shown.		
Skin corrosion/irritation	Health injuries are not known or expected under normal use.	
Serious eye damage/eye irritation	Health injuries are not known or expected under normal use. Direct contact with eyes may cause temporary irritation.	
Eye		
506U78		Acute ocular irritation, Application of 0.1 mL (61 mg, as a solid) resulted in maximum average score of 6.7 (Draize grade 1) Result: Minimal Irritant Species: Rabbit
Respiratory sensitisation	Not available.	
Skin sensitisation	Health injuries are not known or expected under normal use.	
Sensitisation		
506U78		Maximisation assay (Magnusson and Kligman) Result: negative Species: Guinea pig
Germ cell mutagenicity	Health injuries are not known or expected under normal use. Contains a component that produced mutagenicity in laboratory tests.	
Mutagenicity		
506U78		Mouse Lymphoma Cell (L5178Y) Mutation Assay, GLP assay Result: positive SAR / QSAR, DEREK, Lhasa, UK Result: Plausible (chromosome damage)
Carcinogenicity	Health injuries are not known or expected under normal use. Contains a component listed as a carcinogen by: (GSK).	
506U78		SAR / QSAR Result: Plausible
Reproductive toxicity	Health injuries are not known or expected under normal use. Contains components which have been classified as: Suspected of damaging fertility or the unborn child.	
Reproductivity		
506U78		Embryo-foetal development - Intravenous Result: Foetal NOAEL not identified; decreased foetal weight with doses = 300 mg/kg/day (intravenous infusion); delayed foetal skeletal ossification and increased malformations with doses $\geq$ 30 mg/kg/day (lowest dose); maternal NOAEL = 100 mg/kg/day Species: Rabbit

Specific target organ toxicity - single exposure None known.

Specific target organ toxicity - repeated exposure 506U78	May cause damage to organs through prolonged or repeated exposure.
	Repeat dose non-clinical studies; clinical observation Organ: bone marrow; blood; central nervous system; gastrointestinal tract
Aspiration hazard	Not available.
Mixture versus substance information	No information available.
Other information	Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause adverse effects.

SECTION 12: Ecological information

12.1. Toxicity Not expected to be harmful to aquatic organisms.

Components		Species	Test results
506U78 (CAS 121032-29-9)			
Aquatic			
<i>Acute</i>			
Activated Sludge Respiration	IC50	Residential sludge	> 1000 mg/l, 3 hours
Algae	EC50	Green algae (Selenastrum capricornutum)	> 100 mg/l, 96 hours Static test, OECD 201
	NOEC	Green algae (Selenastrum capricornutum)	> 100 mg/l, 96 hours
Crustacea	EC50	Water flea (Daphnia magna)	> 1070 mg/l, 48 hours OECD 202
	NOEC	Water flea (Daphnia magna)	260 mg/l, 48 hours
Fish	EC50	Rainbow trout (Adult Oncorhynchus mykiss)	> 100 mg/l, 96 hours Static , OECD 203
	NOEC	Rainbow trout (Adult Oncorhynchus mykiss)	> 100 mg/l, 96 hours

* Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability

Photolysis

UV/visible spectrum wavelength

506U78 294 nm

Hydrolysis

Half-life (Hydrolysis-neutral)

506U78 > 1 years Measured

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

506U78 40 %, 28 days Modified Zahn-Wellens, Activated sludge

Percent degradation (Aerobic biodegradation-soil)

506U78 48 - 67.9 %, 64 days

12.3. Bioaccumulative potential

Partition coefficient

n-octanol/water (log Kow)

506U78 < 1

12.4. Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

506U78 1.73 - 1.94 Measured, pH 5.5-7.8

Mobility in general

Volatility

Henry's law

506U78 0 atm m³/mol Estimated

12.5. Results of PBT and vPvB assessment Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions). Avoid discharge into water courses or onto the ground.
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.
EU waste code	The Waste code should be assigned in discussion between the user, the producer and the waste disposal company.
Disposal methods/information	Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable regulations.
Special precautions	Dispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations

The product is classified and labelled in accordance with EC directives or respective national laws. This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations

Follow national regulation for work with chemical agents.

15.2. Chemical safety assessment

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations

Not available.

References

GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.

Full text of any statements or R-phrases and H-statements under Sections 2 to 15

R40 Limited evidence of a carcinogenic effect.
R53 May cause long term adverse effects in the aquatic environment.
R62 Possible risk of impaired fertility.
R63 Possible risk of harm to the unborn child.
R68 Possible risk of irreversible effects.
H341 Suspected of causing genetic defects.
H351 Suspected of causing cancer.
H361 Suspected of damaging fertility or the unborn child.
H372 Causes damage to organs through prolonged or repeated exposure.
H413 May cause long lasting harmful effects to aquatic life.

Revision information

Product and Company Identification: Product and Company Identification
Composition / Information on Ingredients: Ingredients
Physical & Chemical Properties:
Transport Information: Agency Name and Packaging Type/Transport Mode Selection
Regulatory Information: United States
GHS: Classification

Training information

Follow training instructions when handling this material.

Disclaimer

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.